Bartsch R et al. Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial. ESMO Breast 2022;Abstract 165MO.
Carey L et al. HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases. ESMO 2021;Abstract 331TiP.
Chumsri S et al. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer 2022;8(1):68. Abstract
Coles CE et al. The Lancet Breast Cancer Commission: Tackling a global health, gender, and equity challenge. Lancet 2022;399(10330):1101-3. Abstract
Cortes J et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143-54. Abstract
Corti C et al. Targeting brain metastases in breast cancer. Cancer Treat Rev 2022;103:102324. Abstract
Curigliano G et al. Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ breast cancer with and without brain metastases (HER2CLIMB). ASCO 2022;Abstract 1043.
Debien V et al. DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade. ASCO 2022;Abstract TPS621.
Giordano SH et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol 2022;40(23):2612-35. Abstract
Hamilton EP et al. Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress). ASCO 2022;Abstract TPS1108.
Krop IE et al. Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). ASCO 2022;Abstract TPS1111.
Ma CX et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer. Clin Cancer Res 2022;28(7):1258-67. Abstract
Mitin N et al. A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. NPJ Breast Cancer 2022;8(1):103. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results from DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
O’Sullivan CCM et al. A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. ASCO 2021;Abstract TPS595.
Ramakrishnan N et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 2022;40(23):2636-55. Abstract
Ren Y et al. Burden of lymphedema in long-term breast cancer survivors by race and age. Cancer 2022;[Online ahead of print]. Abstract
Schmid P et al. Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status of the phase III TROPiCS-02 study. ESMO 2022;Abstract 214MO.